Include more government sites in Febuxostat ER tablet trial: CDSCO Panel Nod tells Akums Drugs
New Delhi: Stating to include more government sites in the trial, the drug major Akum Pharma has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase III clinical trial of the Febuxostat extended-release (ER) tablet 40/80mg.
This recommendation is subject to the condition that the firm should add more government sites for the study.
This came after the drug major Akum Pharma presented the Phase III clinical trial protocol of Febuxostat.
Febuxostat is a medication used to manage and treat hyperuricemia and gout. It is in a class of drugs known as xanthine oxidase inhibitors. Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels.
Febuxostat oral tablet is used to treat hyperuricemia (constantly high levels of uric acid) in adults who have gout. It helps decrease your symptoms of gout. Symptoms of gout include pain, swelling, redness, heat, soreness, and stiffness in certain joints.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.